Wall Street brokerages forecast that Vericel Corp (NASDAQ:VCEL) will announce earnings per share (EPS) of ($0.07) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Vericel’s earnings. The lowest EPS estimate is ($0.07) and the highest is ($0.06). Vericel posted earnings of ($0.15) per share during the same quarter last year, which would indicate a positive year over year growth rate of 53.3%. The business is expected to report its next earnings results on Tuesday, May 14th.
According to Zacks, analysts expect that Vericel will report full-year earnings of $0.07 per share for the current financial year, with EPS estimates ranging from $0.02 to $0.10. For the next financial year, analysts anticipate that the firm will report earnings of $0.27 per share, with EPS estimates ranging from $0.22 to $0.36. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that follow Vericel.
Vericel (NASDAQ:VCEL) last released its quarterly earnings data on Tuesday, February 26th. The biotechnology company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.05 by $0.06. The firm had revenue of $31.34 million for the quarter, compared to analyst estimates of $28.69 million. Vericel had a negative net margin of 8.96% and a negative return on equity of 7.58%. Vericel’s quarterly revenue was up 34.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.01 earnings per share.
Several research firms recently weighed in on VCEL. BidaskClub upgraded shares of Vericel from a “sell” rating to a “hold” rating in a research note on Saturday. Zacks Investment Research lowered shares of Vericel from a “buy” rating to a “hold” rating in a research note on Friday, March 8th. Needham & Company LLC lowered shares of Vericel from a “buy” rating to a “hold” rating and set a $17.92 price objective on the stock. in a research note on Thursday, February 28th. Finally, Oppenheimer began coverage on shares of Vericel in a research note on Tuesday, January 29th. They set an “outperform” rating and a $23.00 price objective on the stock. Three analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. Vericel currently has a consensus rating of “Buy” and an average target price of $20.73.
In other Vericel news, CFO Gerard J. Michel sold 15,625 shares of the firm’s stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $17.64, for a total value of $275,625.00. Following the sale, the chief financial officer now owns 127,047 shares in the company, valued at $2,241,109.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Gerard J. Michel sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, February 11th. The shares were sold at an average price of $17.09, for a total transaction of $170,900.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 43,125 shares of company stock worth $781,875. 4.50% of the stock is owned by company insiders.
Several large investors have recently made changes to their positions in the business. Meeder Asset Management Inc. increased its stake in shares of Vericel by 25.3% in the first quarter. Meeder Asset Management Inc. now owns 7,222 shares of the biotechnology company’s stock valued at $128,000 after purchasing an additional 1,457 shares during the period. Virtu Financial LLC acquired a new stake in shares of Vericel in the first quarter valued at approximately $298,000. Deutsche Bank AG increased its stake in shares of Vericel by 151.1% in the fourth quarter. Deutsche Bank AG now owns 237,992 shares of the biotechnology company’s stock valued at $4,140,000 after purchasing an additional 143,220 shares during the period. American Century Companies Inc. acquired a new stake in shares of Vericel in the fourth quarter valued at approximately $2,275,000. Finally, Geode Capital Management LLC increased its stake in shares of Vericel by 4.6% in the fourth quarter. Geode Capital Management LLC now owns 496,490 shares of the biotechnology company’s stock valued at $8,638,000 after purchasing an additional 21,962 shares during the period. Institutional investors own 83.30% of the company’s stock.
VCEL traded down $2.26 on Wednesday, hitting $16.26. 1,258,757 shares of the company’s stock were exchanged, compared to its average volume of 656,804. The firm has a market cap of $808.29 million, a price-to-earnings ratio of -116.14 and a beta of 3.02. Vericel has a twelve month low of $8.95 and a twelve month high of $21.00.
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns.
Featured Article: Understanding Stock Ratings
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.